Gabby Migliara is a manager of public affairs at PhRMA focusing on the cost and value of medicines. She previously worked with the U.S. Census Bureau on marketing and communications for the 2020 Census campaign. Outside the office, Gabby enjoys trying new restaurants, hanging with her cat and exploring DC neighborhoods.
Recent Posts
Commercial health plans’ transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs for brand medicines
By Gabby Migliara | August 6, 2020
A decade ago, most patients paid only copays for brand medicines. But in recent years, use of deductibles and coinsurance in commercial health plans has skyrocketed. According to a recent IQVIA...
Read More
New data show commercially insured patients face increasingly high cost sharing for brand medicines
By Gabby Migliara | July 30, 2020
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy...
Read More
Payers subject 80% of new RA and MS patients to utilization management restrictions
By Gabby Migliara | July 22, 2020
A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine...
Read More
Study finds the pharmaceutical industry retains a smaller share of revenue than research-intensive industries
By Gabby Migliara | July 14, 2020
A new study from Oxford Economics found the pharmaceutical industry retains a considerably smaller share of total spending on its products than other research-intensive industries, despite...
Read More
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
By Gabby Migliara | June 1, 2020
The two largest pharmacy benefit managers (PBMs), CVS Caremark and Express Scripts, have once again increased the number of medicines on their standard formulary exclusion lists. Medicines...
Read More
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
By Gabby Migliara | April 1, 2020
Recently, PhRMA hosted a teleconference to provide an update on our member companies’ around-the-clock efforts in developing treatments and vaccines for COVID-19, a disease caused by a novel...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
